Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Flare, Doppler Expand XRP Access to FXRP Vaults With New Integration

Flare, Doppler Expand XRP Access to FXRP Vaults With New Integration

CoinEditionCoinEdition2026/10/03 16:39

Flare and Doppler are expanding XRP holders’ access to FXRP vaults through Doppler’s platform, according to posts on X on October 3.

The partnership connects XRP users with Flare-based yield products through Doppler. Rox Park, Doppler’s head of institutions, described the integration as part of the company’s broader financial infrastructure for XRP.

The platform will also give users access to external investment strategies alongside Doppler’s own products. However, each strategy comes with its own risks and operating conditions.

FXRP represents XRP on Flare through its FAssets system. XRP holders can deposit their tokens and receive FXRP for use across decentralized finance applications.

Users can then deploy FXRP across vaults, lending markets and other DeFi products. Flare reported that about 145.2 million FXRP had been issued as of September 24. Additionally, roughly 130 million FXRP had entered DeFi applications.

Doppler said the partnership supports its goal of becoming a financial operating layer for tokenized assets.

The company also reported more than $150 million in deposits across its XRP and RLUSD products.

“More ways to use XRP, without having to look elsewhere,” Doppler said.

Doppler also plans to support additional networks, including Base and Coinbase Wrapped XRP, as it expands its XRP-related financial products.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%